Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

BACKGROUND: Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns of cabozantinib are not well characterized. METHODS: Patients with mRCC treated with cabozantinib between 2011 and 2019 were i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Chun Loo, Dudani, Shaan, Wells, J. Connor, Donskov, Frede, Pal, Sumanta K., Dizman, Nazli, Rathi, Nityam, Beuselinck, Benoit, Yan, Flora, Lalani, Aly‐Khan A., Hansen, Aaron, Szabados, Bernadett, de Velasco, Guillermo, Tran, Ben, Lee, Jae Lyun, Vaishampayan, Ulka N., Bjarnason, Georg A., Subasri, Mathushan, Choueiri, Toni K., Heng, Daniel Y. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926018/
https://www.ncbi.nlm.nih.gov/pubmed/33463028
http://dx.doi.org/10.1002/cam4.3717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926018/
https://www.ncbi.nlm.nih.gov/pubmed/33463028
http://dx.doi.org/10.1002/cam4.3717

Ejemplares similares